Anne-Sofie Houlberg Jensen

Anne-Sofie Houlberg Jensen

Auto-generated profile, based on publicly available information

Anne-Sofie Houlberg Jensen

Department of Clinical Biochemistry, Copenhagen University Hospital - Bispebjerg, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2023 in Liver International
Verified
Journal Article
Open access
AJAnne‐Sofie H. Jensen
Anne‐Sofie H. Jensen
MWMarie Winther‐Sørensen
Marie Winther‐Sørensen
JBJohan Burisch
Johan Burisch
ABAnnika Bergquist
Annika Bergquist
HYHenriette Ytting
Henriette Ytting
NANicolai Wewer Albrechtsen
Nicolai Wewer Albrechtsen
Background and Aims: Patients with some chronic liver diseases have increased risk of diabetes. Whether this is also the case for patients with autoimmune liver diseases is unknown. The study aimed to calculate risk and worldwide prevalence of diabetes in patients with autoimmune hepatitis (AIH), primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC).Methods: We performed a case–control study using data from the United Kingdom Biobank (UKB) and compared frequency of type 1 diabetes (T1D) and type 2 diabetes (T2D) in AIH and PBC with age‐, sex‐, BMI‐ and ethnicity‐matched controls. Next, we performed a systematic review and proportional meta‐analysis searching PubMed, Embase, Cochrane Library and Web of Science (inception to 1 May 2022 [AIH]; 20 August 2022 [PBC]; 11 November 2022 [PSC]). The pooled prevalence of diabetes was calculated using an inverse method random effects model.Results: Three hundred twenty‐eight AIH patients and 345 PBC patients were identified in UKB and risk of T1D and T2D significantly increased compared with matched controls. Our systematic search identified 6914 records including the UKB study. Of these, 77 studies were eligible for inclusion comprising 36 467, 39 924 and 4877 individuals with AIH, PBC and PSC, respectively. The pooled prevalence of T1D was 3.8% (2.6%–5.7%), 1.7% (0.9%–3.1%), 3.1% (1.9%–4.8%) and of T2D 14.8% (11.1%–19.5%), 18.1% (14.6%–22.2%), 6.3% (2.8%–13.3%) in patients with AIH, PBC and PSC, respectively.Conclusions: Patients with autoimmune liver diseases have increased risk of diabetes. Increased awareness of diabetes risk in patients with autoimmune liver diseases is warranted.

31 August 2023 in Hepatology Communications
Verified
Journal Article
Open access
LHLiv E. Hetland
Liv E. Hetland
TKThit M. Kronborg
Thit M. Kronborg
MTMira Thing
Mira Thing
MWMikkel Werge
Mikkel Werge
AJAnders E. Junker
Anders E. Junker
LGLise Lotte Gluud
Lise Lotte Gluud
Introduction: Abdominal ultrasound (US) and CT are important tools for the initial evaluation of patients with liver disease. Our study aimed to determine the accuracy of these methods for diagnosing cirrhosis. Methods: In all, 377 participants from 4 prospective cohort studies evaluating patients with various liver diseases were included. All patients were included between 2017 and 2022 and had undergone a liver biopsy as well as US and/or CT. Using the histological assessment as the gold standard, we calculated diagnostic accuracy for US and CT. Liver biopsies were evaluated by expert histopathologists and diagnostic scans by experienced radiologists. Results: The mean age was 54 ± 14 years and 47% were female. Most patients had NAFLD (58.3%) or alcohol-associated liver disease (25.5%). The liver biopsy showed cirrhosis in 147 patients (39.0%). Eighty-three patients with cirrhosis had Child-Pugh A (56.4% of patients with cirrhosis) and 64 had Child-Pugh B/C (43.6%). Overall, the sensitivity for diagnosing cirrhosis by US was 0.71 (95% CI 0.62–0.79) and for CT 0.74 (95% CI 0.64–0.83). The specificity was high for US (0.94, 95% CI 0.90–0.97) and for CT (0.93, 95% CI 0.83–0.98). When evaluating patients with Child-Pugh A cirrhosis, sensitivity was only 0.62 (95% CI 0.49–0.74) for US and 0.60 (95% CI 0.43–0.75) for CT. For patients with Child-Pugh B/C, sensitivity was 0.83 (95% CI 0.70–0.92) for US and 0.87 (95% CI 0.74–0.95) for CT. When limiting our analysis to NAFLD (20% with cirrhosis), the sensitivity for US was 0.45 (95% CI 0.28–0.64) and specificity was 0.97 (95% CI 0.93–0.99). Conclusion: US and CT show moderate sensitivity and may potentially overlook compensated cirrhosis underlining the need for additional diagnostic testing. Export

22 June 2023 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
AJAnne-Sofie H. Jensen
Anne-Sofie H. Jensen
HYHenriette Ytting
Henriette Ytting
MWMarie Winther-Sørensen
Marie Winther-Sørensen
JBJohan Burisch
Johan Burisch
ABAnnika Bergquist
Annika Bergquist
NANicolai J. Wewer Albrechtsen
Nicolai J. Wewer Albrechtsen
Autoimmune liver diseases include autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis. They are chronic, heterogenous diseases affecting the liver which is a key metabolic organ that ensures glucose homeostasis. It is well known that patients with other chronic liver diseases such as cirrhosis and nonalcoholic fatty liver disease (NAFLD) display glucose disturbances like insulin resistance and have an increased risk of diabetes. Previous evidence on glucose disturbances in patients with autoimmune liver disease is scarce but does point towards a potentially increased risk of type 1 diabetes and type 2 diabetes. The underlying mechanisms are unknown but may reflect genetic predisposition, concurrent NAFLD and or cirrhosis development, and treatment (steroid) related impairment of glucose homeostasis. Therefore, increased awareness and surveillance of diabetes development in patients with autoimmune liver disease may be important. Overall, detection and treatment of diabetes generally follow the usual diabetes guidelines; however, in patients with advanced liver cirrhosis, HbA1c may not be a reliable marker of average glucose levels, and treatment with insulin is generally recommended. In addition, it has recently been suggested that sodium–glucose cotransporter 2 inhibitors may be beneficial in treating refractory ascites. Further research on diabetes risk in autoimmune liver disease is warranted.

1 June 2024 in American Journal of Physiology-Gastrointestinal and Liver Physiology
Verified
Journal Article
Closed access
AJAnne-Sofie H. Jensen
Anne-Sofie H. Jensen
HYHenriette Ytting
Henriette Ytting
MWMikkel Werge
Mikkel Werge
ERElias Badal Rashu
Elias Badal Rashu
LHLiv E. Hetland
Liv E. Hetland
NANicolai Wewer Albrechtsen
Nicolai Wewer Albrechtsen
Patients with autoimmune liver disease but without overt diabetes display glucose disturbances early on in their disease course. We identified pathophysiological traits specific to these patients including altered incretin responses.

1 October 2024 in American Journal of Physiology-Gastrointestinal and Liver Physiology
Verified
Journal Article
Closed access
SKSasha Kjeldsen
Sasha Kjeldsen
MWMikkel P. Werge
Mikkel P. Werge
JGJosephine Grandt
Josephine Grandt
MRMichael M. Richter
Michael M. Richter
MTMira Thing
Mira Thing
NANicolai Wewer Albrechtsen
Nicolai Wewer Albrechtsen
Individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) present with increased plasma levels of glucagon (hyperglucagonemia), irrespective of body mass index (BMI) and type 2 diabetes. Therefore, MASLD and the resultant hyperglucagonemia may act as a diabetogenic risk factor. Notably, hepatic steatosis was a significant contributor to the hyperglucagonemia in MASLD, potentially unveiling a pathway for the hyperglucagonemia in some patients with type 2 diabetes.

17 July 2025 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
AJAnne‐Sofie Houlberg Jensen
Anne‐Sofie Houlberg Jensen
HYHenriette Ytting
Henriette Ytting
ANAnnelaura Bach Nielsen
Annelaura Bach Nielsen
MWMikkel Parsberg Werge
Mikkel Parsberg Werge
ERElias Badal Rashu
Elias Badal Rashu
NANicolai Wewer Albrechtsen
Nicolai Wewer Albrechtsen
Background: Autoimmune hepatitis (AIH) may be difficult to diagnose and distinguish clinically and biochemically from other chronic liver diseases like metabolic dysfunction‐associated steatotic liver disease (MASLD).Aims: To identify pathways involved in the pathogenesis and identify disease‐specific biomarkers of AIH.Methods: We recruited 19 newly diagnosed patients with AIH, 17 with MASLD, and 19 healthy controls. Liver tissue and plasma were collected, and untargeted mass‐spectrometry‐based proteomics was performed. For classification of AIH versus MASLD and healthy, machine learning analyses were performed employing logistic regression models on liver and plasma proteome data. Findings were validated using data from the United Kingdom Biobank (UKB).Results: We identified 7632 liver and 556 plasma proteins with 2521 liver and 227 plasma proteins differing between AIH and healthy, including 56 overlapping. Metabolic dysregulation and systemic immune activation characterised the AIH liver and plasma proteome, respectively. Plasma proteome profiling enabled classification of AIH from MASLD and healthy with an area under the receiver operating characteristic curve of 0.91 (0.09 SD). Validation in the UKB was possible for 8 of 20 diagnostic proteins and showed consistent directional changes. Three proteins (C7, ICAM1, cAST) were significantly different between AIH and MASLD/healthy in unadjusted analyses, and 6 of 8 proteins (C7, ICAM1, cAST, IGFBP3, TIMP1, TTR) were significantly different when adjusting for age and sex.Conclusions: Clinical proteomic analyses of paired liver‐plasma samples from patients with AIH enabled high diagnostic potential. Proteomics may constitute a novel non‐invasive diagnostic tool for AIH if validated in larger, age‐ and sex‐matched cohorts.Clinical Trial Number: NCT05335603